降尿酸治疗对慢性痛风患者心血管影响的系统综述与荟萃分析
该系统综述与荟萃分析检索了痛风患者降尿酸治疗(ULT)的随机试验,评估其对心血管结局的影响。汇总分析未显示非布司他与别嘌醇在心血管事件上存在显著差异(RR 1.69,95%CI 0.54-5.34,P=0.37),任何ULT与安慰剂比较亦无显著差异。
要点
- 非布司他与别嘌醇心血管事件风险无显著差异(RR 1.69,95%CI 0.54-5.34)。
- 任何ULT与安慰剂比较,非抗血小板试验协作组事件及全因死亡率均无显著差异。
- 长期研究中非布司他组心血管事件多于别嘌醇组,结果接近显著。
核心结论
- 随机对照试验数据未提示痛风患者不同降尿酸治疗之间心血管事件存在差异。
- 试验事件数少且随访可能过短,不足以显示通过控制炎症发作和降低尿酸带来的心血管获益。
研究设计与样本
- 系统综述与荟萃分析,检索随机试验,纳入报告降尿酸治疗心血管安全性的合格试验。
- 潜在药物包括别嘌醇、非布司他、培戈洛酶、拉布立酶、丙磺舒、苯溴马隆、磺吡酮、氯沙坦、非诺贝特和SGLT2抑制剂。
主要发现
- 共检索到3084条文献,其中642条重复,初筛后35项研究入选综述。
- 部分试验未报告心血管事件,6项非随机对照试验,4项研究两组均无事件。
- 另外4项研究中非布司他组(n=3631)发生40例事件,别嘌醇组(n=1154)发生5例。
- 非布司他与别嘌醇比较:RR 1.69(95%CI 0.54,5.34),P=0.37。
- 任何ULT与安慰剂比较(8项研究,n=2221):非抗血小板试验协作组事件RR 1.47(95%CI 0.49,4.40),P=0.49;全因死亡率RR 1.45(95%CI 0.35,5.77),P=0.60。
关键数值与推荐
- 非布司他与别嘌醇心血管事件比较RR 1.69(95%CI 0.54,5.34),P=0.37。
- 任何ULT与安慰剂非抗血小板试验协作组事件比较RR 1.47(95%CI 0.49,4.40),P=0.49。
- 任何ULT与安慰剂全因死亡率比较RR 1.45(95%CI 0.35,5.77),P=0.60。
- 长期研究中非布司他与别嘌醇比较结果接近显著,非布司他组心血管事件更多。
临床怎么用
- 现有随机对照试验数据不支持因心血管事件差异而优先选择某种降尿酸药物。
- 对高心血管风险痛风患者,降尿酸治疗的心血管获益仍需更长随访研究验证。
局限性
- 试验事件数少,尽管纳入高危患者,可能随访时间过短不足以显示心血管获益。
- 部分试验未报告心血管事件,6项研究非随机对照试验,4项研究两组均无事件。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To determine if urate-lowering treatment (ULT) in gout can reduce cardiovascular (CV) outcomes. METHODS: Randomized trials were searched for treatment with ULT in gout. Eligible trials had to report CV safety of a ULT. Potential medications included allopurinol, febuxostat, pegloticase, rasburicase, probenecid, benzbromarone, sulphinpyrazone, losartan, fenofibrate and sodium-glucose linked transporter 2 inhibitors. RESULTS: A total of 3084 citations were found, with 642 duplicates. After the primary screen, 35 studies were selected for review. Several trials did not report CV events. Six were not randomized controlled trials (RCTs). Four studies reported no events in either intervention arm while the other four had 40 events in the febuxostat group ( n = 3631) and 5 in allopurinol group ( n = 1154). Overall, the pooled analysis did not show a significant difference between the two [febuxostat vs allopurinol: relative risk (RR) 1.69 (95% CI 0.54, 5.34), P = 0.37]. CV events did not decrease over time. Comparing shorter studies (<52 weeks) to longer ones did not reveal any statistical differences. However, in long-term studies with febuxostat vs allopurinol, results were nearly significant, with more CVE occurring with febuxostat treatment. Comparing any ULT to placebo (eight studies, n = 2221 patients) did not demonstrate a significant difference in non-Anti-Platelet Trialists' Collaboration events [any ULT vs placebo: RR 1.47 (95% CI 0.49, 4.40), P = 0.49] or all-cause mortality [any ULT vs placebo: RR 1.45 (95% CI 0.35, 5.77), P = 0.60]. CONCLUSION: RCT data do not suggest differences in CV events among ULTs in gout. Trials had few events despite high-risk patients being enrolled and may have been too short to show CV reduction by controlling inflammatory attacks and lowering uric acid.
引用
- Zhang T, Pope JE. Cardiovascular effects of urate-lowering therapies in patients with chronic gout: a systematic review and meta-analysis. Rheumatology (Oxford). 2017. PMID: 28379501. doi:10.1093/rheumatology/kex065
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。